rdf:type |
|
lifeskim:mentions |
umls-concept:C0036043,
umls-concept:C0066546,
umls-concept:C0205531,
umls-concept:C0220825,
umls-concept:C0226896,
umls-concept:C0324336,
umls-concept:C0442027,
umls-concept:C0596611,
umls-concept:C0961781,
umls-concept:C1521801,
umls-concept:C1527415,
umls-concept:C1704939
|
pubmed:issue |
1
|
pubmed:dateCreated |
2010-1-1
|
pubmed:abstractText |
To determine whether signs of avermectin (AVM)-milbemycin (MB) toxicosis would be evident in AVM-MB-sensitive Collies after treatment with an experimental formulation of spinosad alone or spinosad combined with MB 5-oxime (MBO) at doses up to 5 and 10 times the MBO maximum label dose.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0002-9645
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
71
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
115-9
|
pubmed:meshHeading |
pubmed-meshheading:20043790-Animals,
pubmed-meshheading:20043790-Anthelmintics,
pubmed-meshheading:20043790-Dog Diseases,
pubmed-meshheading:20043790-Dogs,
pubmed-meshheading:20043790-Dose-Response Relationship, Drug,
pubmed-meshheading:20043790-Drug Combinations,
pubmed-meshheading:20043790-Drug Therapy, Combination,
pubmed-meshheading:20043790-Heterozygote,
pubmed-meshheading:20043790-Homozygote,
pubmed-meshheading:20043790-Macrolides,
pubmed-meshheading:20043790-Mutation,
pubmed-meshheading:20043790-P-Glycoprotein
|
pubmed:year |
2010
|
pubmed:articleTitle |
Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation.
|
pubmed:affiliation |
Elanco Animal Health, Greenfield, IN 46140, USA. shermanjg@lilly.com
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|